English  |  正體中文  |  简体中文  |  Items with full text/Total items : 85375/114038 (75%)
Visitors : 22753969      Online Users : 840
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://nccur.lib.nccu.edu.tw/handle/140.119/122269


    Title: 新藥進入台灣健保市場准入委外顧問業商機與發展策略之探討 – 以A公司為例
    The Study of Business Opportunities and Development Strategies of the Consultant for Pharmaceutical Market Access
    Authors: 廖永良
    Liao, Yung-Liang
    Contributors: 李易諭
    Lee, Yih-Yuh
    廖永良
    Liao, Yung-Liang
    Keywords: 新藥
    市場准入
    核價
    健保給付
    委外
    政策
    價值
    New drug
    Market access
    Reimbursement
    Out sourcing
    Policy
    Value
    Date: 2019
    Issue Date: 2019-02-12 15:43:46 (UTC+8)
    Abstract: 委外服務可為公司帶來節省人力、降低營運成本、提升績效等益處,在各行各業極為平常。新藥進入台灣健保市場准入是一個新興的工作領域,委外服務更是此新興工作領域所衍生的新商機。本研究目的探討藥廠委外的內部決策關鍵因素,以及委外服務業影響藥廠委託案件的公司本質,經由質化與量化資料的收集與分析,來提供個案公司未來營運與發展策略建議。

    本研究是以「個案研究法」,透過藥廠、個案公司市場准入人員的焦點團體訪談方式來進行。研究分析結果指出,藥廠委外的內部決策關鍵因素共有13個項目,最大的關鍵因素是專業能力改善中的「增進核價策略能力」(權重值:0.151),而這項目也是個案公司最能滿足藥廠需求的部分(加權評分差異值:0.604),個案公司只有在「引進技術能力,如經濟效益、預算衝擊」、「協助與國外部門溝通」等方面劣於競爭廠商。委外服務業影響藥廠委託案件的公司本質共有10個項目,最大的影響項目是市場面中的的「當地承接案件經歷」(權重值:0.150),而這項目也是個案公司最能滿足藥廠委託的公司本質(加權評分差異值:0.750),個案公司則在資源面全部三個項目、市場面的「積極獲利的非專業行為」劣於競爭廠商。

    研究結果呼應了個案公司勝出的是人力資源的專業素質與工作經驗,跨國競爭廠商勝出的是總公司資源支援與市場面中的「積極獲利的非專業行為」。個案公司可朝著維持或增強人力專業素質,進一步與國內外其它單位聯盟合作,善用的外部資源補足自我不足,是持續增長、增加競爭優勢的最快方式。
    Data show that outsourcing service could decrease the inner manpower, save the operation cost and increase performance. It is general for of a company in different field to outsource a job. The new drug access to NHI market is a new developed job field and the outsourcing service of new drug access to NHI market is as new developed business opportunity. The purpose of this study is going to know the key decision factor for the pharmaceutical company outsourcing new drug access job. Furthermore, it is going to know which profile of service providers influence the pharmaceutical company’s outsourcing decision. Both qualitative and quantitative data are collected and analyzed for advising future strategic development for case company

    This is a case study research, inviting the market access staff from the pharmaceuticals and case company for focus group interviews respectively. The final analysis showed that there were 13 key items influencing pharmaceutical companies to outsource new drug access to NHI market. The greatest factor was “increase the capability of pricing strategy (weight value: 0.151).” Interestingly, it was also the most important item which the case company could satisfied with the pharmaceutical company’s need (difference of weight grade: 0.604). The case company was only inferior to the competitor in the items of “import technologic skills e.g. health economics & outcomes research and budget impact” and “assist in communicating with head office. “There were 10 profile items of service provider influencing the pharmaceutical company’s outsourcing decision. The greatest factor was “local market access experience of the service provider (weight value: 0.150).” Interestingly, it was also the most important item which the case company could satisfied with the pharmaceutical company’s need (difference of weight grade: 0.750). The case company was inferior to the competitor in all 3 items of company resource related dimension and in the item of “non-professional but beneficial behavior” of market related dimension.

    The study results referred to the original strengths of the case company which were professional capability and abundant work experience of human resources. The strengths of international competitors were resources support from head office and non-professional but beneficial behavior of market dimension. Suggest the case company maintain or increase the power of human resources and further keep collaboration with local or foreign alliances. Therefore, good use of outside resources for supplementing inner deficiency will be the quickest way to grow and increase competitive advantages.
    Reference: 一、中文文獻
    方博亮、林祖嘉(2017)。管理經濟學(五版) 。台北:智勝文化。
    吳安妮、劉俊儒 (2001)。員工面、內部營運面,及顧客面對財務績效影響之實證研究。台灣管理學刊 1(1),125-150。
    國立民(2018)。經濟學私房筆記。台北:信樺文化。
    陳志豪、張可臻 & 林忠順(2012)。全民健保單一保險制度的優缺點。家庭醫學與基層醫療,27(6),222-225。
    陳昭姿(2014)。歷年健保新藥管理趨勢回顧。衛生福利部醫療爭議審議報導系列53 特刊。
    陳昭姿(2015)。你吃的藥有效嗎?天下雜誌,577期。2018年10月7日,檢自:https://www.cw.com.tw/article/article.action?id=5069368
    陳昭姿(2016)。如何克服新藥健保核價的困境:共同擬定會議看新藥核價的現況與問題。台北:台灣藥品行銷暨管理協會。
    陳昭姿(2018)。新藥可近性論壇:新藥可近性的挑戰與對策。台北:台灣藥品行銷暨管理協會。
    經濟部(2017)。2017年中小企業白皮書。經濟部中小企業處。
    瑞姆.夏藍(2005)。CEO要你知道的事(胡瑋珊譯)。台北:天下文化 (原著出版年:2001)
    衛生福利部中央健康保險署(2018)。全民健康保險高費用癌症藥品送審原則。衛生福利部中央健康保險署中華民國107年6月7日健保審字第1070007670號函。

    二、英文文獻
    Gereffi, G., & Fernandez-Stark, K. (2016). Global value chain analysis: A primer. Duke CGGC.
    Ghodeswar, B., & Vaidyanathan, J. (2008). Business process outsourcing: An approach to gain access to world-class capabilities. Business Process Management Journal, 14(1), 23-38.
    Hwang, C. L., & Yoon, K. (1981). Methods for multiple attribute decision making. In Multiple attribute decision making (pp. 58-191). Springer, Berlin.
    Possnert, M., Svensson, M., & Ecarla, F. (2009). Managing the fourth hurdle. Uppsala Universitet.
    Sendyona, S. (2014). A payer’s perspective to pharmaceutical market access: Defining market access. Value in Health, 17(7), A428.
    Sendyona, S., Odeyemi, I., & Maman, K. (2016). Perceptions and factors affecting pharmaceutical market access: Results from a literature review and survey of stakeholders in different settings. Journal of Market Access & Health Policy, 4(1), 31660., Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040822/pdf/JMAHP-4-31660.pdf
    Sobrio A, Boggio F. (2011), “Have you optimized your Market Access Efforts?” Pharmaceutical Executive Global Digest. Chester, UK: Advanstar Communications (U.K.) Ltd.

    三、網站部份
    財團法人醫藥品查驗中心(2014)。查驗中心醫藥科技評估組受理諮詢案件之流程說明。2018年9月15日,檢自:http://www.cde.org.tw/HTA/documents
    財團法人醫藥品查驗中心。醫藥科技評估業務HTA。2018年10月6日,檢自:http://cde.org.tw/business/2/Pages/%e9%86%ab%e8%97%a5%e7%a7%91%e6%8a%80%e8%a9%95%e4%bc%b0%e6%a5%ad%e5%8b%99.aspx
    財團法人醫藥品查驗中心。醫藥科技評估Q&A,何謂醫療科技評估?2018年10月4日,檢自:http://cde.org.tw/FAQ/HTA/Pages/%E9%86%AB%E8%97%A5%E7%A7%91%E6%8A%80%E8%A9%95%E4%BC%B0.aspx
    黃莉茵、譚延輝(2009)。病患的經驗與醫療科技評估。2018年9月12日,檢自:http://www2.cde.org.tw/HTA/SubLink/%E7%97%85%E6%82%A3%E7%9A%84%E7%B6%93%E9%A9%97%E8%88%87%E9%86%AB%E7%99%82%E7%A7%91%E6%8A%80%E8%A9%95%E4%BC%B0.pdf
    經濟部(2017)。中小企業處即時新聞(2017年7月20日)。2018年9月12日,檢自:https://www.moea.gov.tw/MNS/populace/news/News.aspx?kind=1&menu_id=40&news_id=68489
    衛生福利部中央健康保險署(2017)。全民健康保險藥物給付項目及支付標準。2018年10月6日,檢自:https://www.nhi.gov.tw/Content_List.aspx?n=662F82A7CEF597C3&topn=3FC7D09599D25979
    衛生福利部中央健康保險署(2014)。全民健康保險藥物給付項目及支付標準共同擬訂會議及辦法。2018年10月2日,檢自:https://www.nhi.gov.tw/Content_List.aspx?n=748D4A0C0839220C&topn=3FC7D09599D25979
    衛生福利部中央健康保險署。新藥及新藥材病友意見分享。2018年10月2日,檢自:https://www1.nhi.gov.tw/PatientShare/PatientShare.aspx
    衛生福利部中央健康保險署(2017)。新藥建議全民健康保險收載作業手冊。2018年10月3日,檢自:https://www.nhi.gov.tw/Content_List.aspx?n=C483A04FFF5E41F9&topn=3FC7D09599D25979
    鄭燕淑(2017)。風傳媒觀點投書:為何醫療科技評估制度需要納入病友團體聲音。2018年10月4日,檢自:http://www.storm.mg/article/237185
    Health technology assessment, Retrieved October, 9, 2018, WHO, from http://www.who.int/health-technology-assessment/en/
    Description: 碩士
    國立政治大學
    經營管理碩士學程(EMBA)
    105932182
    Source URI: http://thesis.lib.nccu.edu.tw/record/#G0105932182
    Data Type: thesis
    DOI: 10.6814/THE.NCCU.EMBA.021.2019.F08
    Appears in Collections:[經營管理碩士學程EMBA] 學位論文

    Files in This Item:

    File SizeFormat
    218201.pdf6431KbAdobe PDF0View/Open


    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告
    1.本網站之數位內容為國立政治大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,惟仍請適度,合理使用本網站之內容,以尊重著作權人之權益。商業上之利用,則請先取得著作權人之授權。
    2.本網站之製作,已盡力防止侵害著作權人之權益,如仍發現本網站之數位內容有侵害著作權人權益情事者,請權利人通知本網站維護人員(nccur@nccu.edu.tw),維護人員將立即採取移除該數位著作等補救措施。
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback